The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics
Status:
Completed
Trial end date:
2020-10-23
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the
effect of mild and moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics
of selatogrel (ACT-246475).